BioCentury | Oct 20, 1997
Finance

Attention getting

...CNTO) would to own 24 percent after the IPO. A group of VCs - including DSV Partners...
BioCentury | Jul 15, 1996
Finance

Guilt by association

...treat infectious diseases, primarily those resistant to existing anti-infectives. A group of VCs - including DSV Partners...
BioCentury | Oct 23, 1995
Emerging Company Profile

Apollon Inc.

...and autoimmune diseases Number of employees: 39 Funds raised: $14 million Funding sources: Centocor Inc., DSV Partners...
Items per page:
1 - 3 of 3
BioCentury | Oct 20, 1997
Finance

Attention getting

...CNTO) would to own 24 percent after the IPO. A group of VCs - including DSV Partners...
BioCentury | Jul 15, 1996
Finance

Guilt by association

...treat infectious diseases, primarily those resistant to existing anti-infectives. A group of VCs - including DSV Partners...
BioCentury | Oct 23, 1995
Emerging Company Profile

Apollon Inc.

...and autoimmune diseases Number of employees: 39 Funds raised: $14 million Funding sources: Centocor Inc., DSV Partners...
Items per page:
1 - 3 of 3